Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
Schernthaner G, Shehadeh N, Ametov AS, Bazarova AV, Ebrahimi F, Fasching P, Janež A, Kempler P, Konrāde I, Lalić NM, Mankovsky B, Martinka E, Rahelić D, Serafinceanu C, Škrha J, Tankova T, Visockienė Ž.
Schernthaner G, et al. Among authors: rahelic d.
Cardiovasc Diabetol. 2020 Oct 23;19(1):185. doi: 10.1186/s12933-020-01154-w.
Cardiovasc Diabetol. 2020.
PMID: 33097060
Free PMC article.
Review.